Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

Paolo Correction Monini, Cecilia Sgadari, Maria Gabriella Grosso, Stefania Bellino, Antonio Di Biagio, Elena Toschi, Ilaria Bacigalupo, Michela Sabbatucci, Giulia Cencioni, Emanuela Salvi, Patrizia Leone, Barbara Ensoli, G. Barillari, G. Moracci, L. Carratelli, G. Gatti, L. Brambilla, M. Brambati, S. Ferrucci, O. De PitàM. A. Pilla, A. Di Carlo, M. Giuliani, F. Cottoni, M. A. Cuccuru, S. Calvieri, R. Clerico, C. Potenza, U. Tirelli, C. Simonelli, F. Martellotta, R. Strumia, A. Borghi, S. Del Giacco, L. Moi, G. Piludu, M. C. Sirianni, M. Campagna, L. Sarmati, M. Andreoni, G. Bianchini, J. Sheldon, J. Milzer, T. Schulz

Research output: Contribution to journalArticlepeer-review

Abstract

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.

Original languageEnglish
Pages (from-to)534-538
Number of pages5
JournalAIDS (London, England)
Volume23
Issue number4
DOIs
Publication statusPublished - Feb 20 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir'. Together they form a unique fingerprint.

Cite this